Latest News

  • INNOVATION

    25 Feb 2026

    Can AI Rethink How New Drugs Are Found?

  • PARTNERSHIPS

    24 Feb 2026

    Lilly Deepens AI Push in Obesity Drug Race

  • INVESTMENT

    23 Feb 2026

    Another Shot in the Obesity Gold Rush

  • MARKET TRENDS

    19 Feb 2026

    Precision Medicine Rises as Biomarkers Drive Change

Pfizer Steps Up Obesity Push With Metsera Deal

Pfizer corporate logo displayed outside office building

PARTNERSHIPS

17 Feb 2026

US drugmaker agrees multibillion-dollar acquisition to bolster metabolic pipeline and challenge leaders in weight-loss therapies

Smartphone showing glucose tracking app beside an arm-worn glucose sensor.

TECHNOLOGY

21 Aug 2025

AI Joins the Fight Against Obesity

FDA clears Dexcom and Signos tools as insurers and clinicians weigh digital alternatives to costly weight-loss drugs

Close-up of Wegovy semaglutide injection pens arranged in rows.

REGULATORY

17 Aug 2025

Conditional FDA Approval Puts Wegovy on Watch

US regulator clears Novo Nordisk drug for MASH, but continued approval to depend on long-term trial data

Hand holding smartphone with Superluminal logo against red tech-themed background.

INSIGHTS

14 Aug 2025

The Next Obesity Breakthrough Could Be Written in Code

Eli Lilly partners with Superluminal to tap Al for faster obesity drug discovery beyond injectables.

Brown pill bottles labeled Aleniglipron with white tablets on a gray surface.

INVESTMENT

7 Aug 2025

Structure Extends Runway to 2027 Ahead of Key 2025 Data

Structure raised $300M to advance its oral GLP-1 pill, with key data due in 2025 and cash runway into 2027.

Eli Lilly sign in front of modern corporate building on a sunny day.

PARTNERSHIPS

26 Jul 2025

One Shot for Cholesterol? Lilly Thinks the Future Is Here

Lilly's Verve buyout could turn lifelong cholesterol drugs into a one-time genetic fix.

Gloved hand uses tweezers to edit a DNA strand against a blue background.

INNOVATION

28 Jun 2025

CRISPR’s Bold Bet: One Shot to Disrupt Cholesterol Care

CTX310 shows up to 86% LDL reduction in early trial, with full results expected in 2025

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.